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328Objective: Risk-stratifying algorithms are currently used to determine which patients may be at prohibitive risk
for surgical aortic valve replacement, and thus candidates for transcatheter aortic valve implantation. Minimally
invasive surgical approaches have been successful in reducing morbidity and improving survival after aortic
valve replacement, especially in octogenarians. We documented outcomes after minimally invasive aortic valve
replacement in high-risk octogenarians who may be considered candidates for percutaneous/transapical aortic
valve replacement.
Methods: From 1996 to 2009, minimally invasive aortic valve replacement was performed in 249 consecutive
octogenarians. We used the modified European System for Cardiac Operative Risk Evaluation and Society of
Thoracic Surgeons score to risk-stratify patients and characterize all early and late results.
Results: The mean age at operation was 84  3 (range 80–95) years, and 111 patients (45%) were male.
Twenty-one percent (n ¼ 52) had previous cardiac surgery. Operative mortality was 3% (n ¼ 8/249). The
median modified European System for Cardiac Operative Risk Evaluation (11%; interquartile range, 6–14)
and Society of Thoracic Surgeons score (10.5%; interquartile range, 7–17) were not predictive of 30-day mor-
tality in this cohort of patients (European System for Cardiac Operative Risk Evaluation c-index ¼ 0.527,
P ¼ .74, Society of Thoracic Surgeons score c-index ¼ 0.67, P ¼ .18). Despite their poor predictive power,
the Society of Thoracic Surgeons score and European System for Cardiac Operative Risk Evaluation were cor-
related with each other (r ¼ 0.40, P<.0001). Postoperative complications included stroke in 10 patients (4%),
pneumonia in 3 patients (1%), renal failure requiring dialysis in 2 patients (1%), cardiac arrest in 2 patients
(1%), pulmonary embolism in 1 patient (1%), and sepsis in 1 patient (1%). Follow-up was available for 238
patients (96%) and extended up to 12 years. Overall, long-term survival after minimally invasive aortic valve
replacement at 1, 5, and 10 years was 93%, 77%, and 56%, respectively. There was no significant difference
in long-term survival compared with that of a US age- and gender-matched population (standardized mortality
ratio, 1.01; 95% confidence interval, 0.76–1.37; P ¼ .88). A multivariate Cox-proportional hazards model in-
dicated that increasing age (hazard ratio, 1.10; P¼ .008) and severe chronic obstructive pulmonary disease (haz-
ard ratio, 2.52; P<.007) were significant predictors of survival. By using these factors, a clinical prediction
model (P ¼ .02) was developed and demonstrated that low-risk patients (first quartile prediction score) had
1-, 5-, and 8-year survival of 94%, 84%, and 67%, whereas high-risk patients (third quartile prediction score)
had 1-, 5-, and 8-year survival of 89%, 74%, and 49%, respectively.
Conclusions: Patients thought to be high-risk candidates for surgical aortic valve replacement have excellent
outcomes after minimally invasive surgery with long-term survival that is no different than that of an age-
and gender-matched US population. These data provide a benchmark against which outcomes of transcatheter
aortic valve implantation could be compared. (J Thorac Cardiovasc Surg 2011;141:328-35)Aortic valve replacement (AVR) for the treatment of severe
and symptomatic aortic stenosis (AS) is the standard of
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The Journal of Thoracic and Cardiovascular Surglogic advancement in percutaneous approaches to achieve
aortic valve implantation.1-6 However, because of
excellent outcomes after AVR even in high-risk patients,7
innovative approaches such as transcatheter aortic valve im-
plantation (TAVI) have been reserved for patients with se-
vere AS deemed to be at very high or prohibitive surgical
risk. In this inoperable cohort, a recent prospective multi-
center TAVI trial demonstrated a procedural success rate ex-
ceeding 90%, with a 30-day and 1-year cumulative
mortality rate of 10.4% and 22.1%, respectively.6 These
statistics are consistent with other single-institution studies
that have gained a vast experience in TAVI.5,8
The decision-making process that ultimately determines
which patients are at prohibitive risk for AVR has recentlyery c February 2011
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
COPD ¼ chronic obstructive pulmonary
disorder
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
HR ¼ hazard ratio
MiniAVR ¼ minimally invasive aortic valve
replacement
OR ¼ odds ratio
STS ¼ Society of Thoracic Surgeons
STS-PROM ¼ Society of Thoracic Surgeons
Predicted Risk of Mortality
TAVI ¼ transcatheter aortic valve
implantation
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Dcome into question.9 Ideally, clinical decision-making
would consist of a physician’s assessment of a patient’s
overall health and his/her suitability to tolerate cardiac
surgery. In recent years, surgical scoring systems have
been developed to use a wide array of preoperative variables
in an effort to accurately determine a patient’s risk of mor-
tality.10,11 The models that have been predominantly
implemented into clinical practice are the European
System for Cardiac Operative Risk Evaluation
(EuroSCORE)10 and the Society of Thoracic Surgeons Pre-
dicted Risk of Mortality (STS-PROM) score.11 Although
some studies have found these models to be highly accurate
and predictive of operative morbidity and mortality,12,13
there is increasing evidence that these models may be less
accurate at predicting outcomes in patients who are at
extreme ends of the risk spectrum.14,15 Recent studies
have found that these scoring systems do not account for
clinical and anatomic characteristics (ie, patient frailty
and a porcelain aorta6) that are thought to be highly relevant
to a patient’s ability to tolerate AVR. As a result, there is
concern in the surgical community that reliance on these
prediction models may inappropriately direct patients to
TAVI when in fact, they may be good surgical candidates.
It is our contention and that of others14 that AVR can be
performed safely in high-risk patients.14,16-18 Although
retrospective in nature and limited by treatment bias,
studies have shown that AVR in octogenarians can be
achieved with an operative mortality as low as 5.9%17
and 1- and 5-year survivals of up to 90% and 70%, respec-
tively.18 Since the introduction of minimally invasive car-
diac surgery by Svensson,19 Cosgrove and Sabik,20 and
our group at Brigham and Women’s Hospital,21 we have
continued to perform the majority of isolated AVRs through
a minimally invasive approach (MiniAVR) in almost allThe Journal of Thoracic and Cacircumstances, including reoperations.16-18,22,23 Our
experience with MiniAVR has demonstrated that patients
benefit from decreased length of hospital stay, as well as
decreased morbidity and dependence on rehabilitation
services after discharge.24 As such, we believe these favor-
able outcomes are likely to be amplified in patients at high
risk of perioperative morbidity.
We hypothesized that the current trend in cardiac surgery
to move toward percutaneous restorative interventions may
have failed to acknowledge the success and safety of open
replacement. Furthermore, we believe that current risk-
prediction models may overestimate risk in appropriately
chosen and optimized patients, leading some to recommend
interventional techniques over traditional approaches. As
such, the purpose of this study is to assess the reliability
of the current risk-prediction models for patients undergo-
ing MiniAVR. In addition, we aim to evaluate immediate
perioperative outcomes after isolated MiniAVR in octoge-
narians who might otherwise be considered candidates for
TAVI. Finally, our third objective is to document long-
term survival to serve as a benchmark for outcomes after
TAVI.MATERIALS AND METHODS
The main objective of this study is to identify and examine a cohort of
patients who would serve as comparable group of patients to those being
offered TAVI currently, and potentially in the future. Our inclusion criteria
consisted of all patients aged more than 80 years who underwent AVR us-
ing a minimally invasive hemi-upper sternotomy (MiniAVR) approach. Ex-
clusion criteria consisted of those who underwent concomitant surgical
procedures, because these patients are generally not offered TAVI and out-
comes would not be directly comparable to high-risk patients undergoing
isolated TAVI.
On the basis of these criteria, 249 consecutive octogenarians underwent
isolatedMiniAVR by 12 surgeons between August 29, 1996, andMarch 17,
2009. Preoperative, hemodynamic, operative, and postoperative character-
istics were captured via a prospectively collected database modeled after
STS national database criteria.11 To risk stratify patients, the STS-
PROM11 was calculated for each patient. Because of significant limitations
in interpretability of both the additive and logistic EuroSCORE, the mod-
ified EuroSCORE25 (a distinct score from both the additive and logistic
score), which has been shown to enhance the accuracy and clinical rele-
vance of both the additive and logistic EuroSCORE,25 was calculated for
all patients. Primary end points included all-cause 30-day mortality,
180-day mortality, stroke, sepsis, reoperation for bleeding, need for hemo-
dialysis, and long-term survival. Survival data were obtained from clinical
visits and correspondence from consulting physicians. The Brigham and
Women’s Institutional Review Board approved this study.
Statistical Analysis
Demographic and other patient-related data were obtained from Brig-
ham and Women’s Hospital medical records. Continuous variables are ex-
pressed as a mean  standard deviation or median with interquartile range
(IQR) in situations where covariates are not normally distributed. Categoric
variables are expressed as a percentage. Because our prospective clinical
research database is modeled after the STS national database, the STS-
PROM score was directly calculated for each patient according to the
most recently released formula.11 The logistic and additive EuroSCOREs
were calculated after the necessary STS covariate manipulation26; theserdiovascular Surgery c Volume 141, Number 2 329
TABLE 1. Preoperative, hemodynamic, and operative characteristics
Preoperative characteristics
Age, y 84  3 (80, 95)
Male gender 111 (45%)
Smokers 124 (61%)
Diabetes 38 (15%)
Hypercholesterolemia 141 (57%)
Hypertension 154 (76%)
Prior CVA 10 (5%)
Infectious endocarditis 8 (4%)
Severe chronic lung disease 31 (15%)
Peripheral vascular disease 34 (17%)
Cerebrovascular disease 26 (13%)
Previous cardiac surgery 52 (21%)
Previous CABG 45 (18%)
Previous valve 14 (6%)
CHF 118 (47%)
Angina 60 (24%)
NYHA class
I/II 93 (46%)
III/IV 110 (54%)
Baseline creatinine 1.29  0.5
Renal failure requiring dialysis 20 (8%)
Hemodynamic characteristics
Ejection fraction 57  11
Congestive heart failure 118 (47%)
Mean PA pressure 24  9
Aortic stenosis 184 (91%)
Mean aortic gradient 50  20
Moderate or greater AR 81 (40%)
Operative characteristics
CPB time 111  49
Crossclamp time 71  28
CVA, Cerebrovascular accident; CABG, coronary artery bypass grafting; CHF, con-
gestive heart failure; NYHA, New York Heart Association; PA, pulmonary artery;
AR, aortic regurgitation; CPB, cardiopulmonary bypass.
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found to be a more accurate predictor of mortality.25 The linear relationship
between the STS score and modified EuroSCORE was assessed with a lin-
ear regression model and Pearson correlation coefficient. The performance
of the modified EuroSCORE and STS-PROM in determining the discrim-
inatory ability of predicted mortality versus actual 30-day mortality was
then assessed using a c-index. The c-index is a statistic that represents
the area beneath the receiver operator curve with values ranging from
0.50 (random chance with no discriminatory ability) to 1.0 (perfect
discrimination).27 A Hosmer–Lemeshow statistic was then used to deter-
mine model calibration of the EuroSCORE and STS score for our study
population.
Univariate predictors of 30-day and 6-month survival were identified
and multivariate analyses were performed using an automated stepwise
backward covariate selection. Long-term survival analysis was initially
performed by comparing survival of the overall patient cohort with
expected mortality rates from the US Census Bureau 2002 national life-
tables by means of a 1-sample log-rank test28; differences between an
age- and gender-matched population were assessed bymeans of a standard-
ized mortality ratio.28 We subsequently attempted to build a long-term sur-
vival prediction model. Model selection was performed using the approach
described by Collett29 (pages 80–89) and is briefly described in this article.
After univariate analysis for each preoperative and hemodynamic predic-
tor, those with a parameter P value less than .15 were selected for initial330 The Journal of Thoracic and Cardiovascular Surgentry into the multivariate model. After initial fitting, nonsignificant vari-
ables were eliminated using backward selection (P<.1). Nonsignificant
univariate predictors were subsequently tested using forward selection
(P ¼ .1), and all possible 2-way interactions were tested using forward se-
lection (P¼ .1 for entering). Finally, all nonsignificant main effects (unless
a component of an interaction term) and nonsignificant interactions were
removed at a P value less than .05. The proportional hazards assumption
was evaluated for all significant predictors; for those assumptions that
did not hold, interaction terms with follow-up time were evaluated to allow
for hazard ratio (HR) variation. To assess the discriminatory ability of the
final model, a Kaplan–Meier survival curve of patients in the 3 tertiles of
the linear predictor was created. SAS version 9.1 (SAS Institute Inc,
Cary, NC) was used for statistical analysis.
RESULTS
As shown in Table 1, mean age at operation was 84  3
years (range, 80–95 years), and 45% (n ¼ 111) of patients
weremale. Approximately 21% (n¼ 52) of patients had pre-
vious cardiac surgery. Mean cardiopulmonary bypass and
crossclamp times were 111  49 minutes and 71  28 min-
utes, respectively. Postoperative complications included
stroke in 10 patients (4%), reoperation for bleeding in 9 pa-
tients (4%), pneumonia in 3 patients (1%), renal failure re-
quiring dialysis in 2 patients (1%), cardiac arrest in
2 patients (1%), pulmonary embolism in 1 patient (1%),
and sepsis in 1 patient (1%). Three patients (2%) required
intra-aortic balloon pump support postoperatively.Meanven-
tilator duration was 16  27 hours, and operative (30-day)
mortality was 3% (n ¼ 8/249). Reoperative MiniAVR had
an operative morality of 3% (n¼ 2), and postoperative com-
plications included stroke in 4 patients (8%), reoperation for
bleeding in 3 patients (6%), pneumonia in 1 patient (2%),
cardiac arrest in 2 patients (4%), and pulmonary embolism
in 1 patient (2%). Mean ventilator duration was 24  42
hours for patients undergoing reoperative MiniAVR.
Univariate analysis of 30-day mortality in the total cohort
identified the only predictor of operative mortality to be
postoperative stroke (odds ratio [OR], 9.5; P ¼ .002). The
modified EuroSCORE (11%, IQR 6%, 14%) and STS
score (10.5%, IQR 7%, 17%) were not predictive of 30-
day mortality in this cohort of patients (EuroSCORE
c-index ¼ 0.527, P ¼ .74, STS score c-index ¼ 0.67,
P¼ .18). The Hosmer–Lemeshow statistic for the modified
EuroSCORE (chi-square, 6.32; P ¼ .50) and STS score
(chi-square, 8.52; P ¼ .38) confirmed that neither scoring
system was effective at predicting mortality in this cohort
of patients. Despite their poor predictive power, however,
the STS score and EuroSCORE were significantly corre-
lated (r ¼ 0.40, P< .0001). The linear regression model
shown in Figure 1 graphically represents this mathematic
relationship (modified EuroSCORE ¼ 6.61 þ 10.01*STS
score).
The cumulative incidence of mortality at 6 months post-
operatively was 6% (n¼ 16). Predictors of 6-monthmortal-
ity were female gender (OR, 3.5; P ¼ .003), preoperative
renal failure (OR, 4.4; P ¼ .03), severe chronic obstructiveery c February 2011
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FIGURE 1. Relationship of modified EuroSCORE and STS score. Euro-
SCORE, European System for Cardiac Operative Risk Evaluation; STS,
Society of Thoracic Surgeons.
TABLE 2. Clinical prediction score characteristics
Clinical prediction score
Mean  SD 93  4
First quartile 89
Median 92
Third quartile 95
Calculated by computing 1.1*ageþ2.43*severe COPD
SD, Standard deviation; COPD, chronic obstructive pulmonary disorder.
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Dpulmonary disorder (COPD) requiring oral steroid treat-
ment (OR, 3.62; P ¼ .02), and postoperative stroke (OR,
9.5; P ¼ .002). A multivariate logistic regression model in-
dicated that when adjusted for each other, female gender
(OR, 3.5; P ¼ .05) and severe COPD (OR, 3.33; P ¼ .04)
were the most significant independent contributors to
6-month mortality.
Follow-up was available for 238 patients (96%) and ex-
tended up to 12 years (3.3  2.7). Overall, long-term sur-
vival after MiniAVR at 1, 5, and 10 years was 91%,
77%, and 56%, respectively. With the use of 2002 US Cen-
sus data, there was no significant difference in long-term
survival compared with that of an age- and gender-
matched population (standardized mortality ratio, 1.01;
95% confidence interval, 0.76–1.37; P ¼ .88; Figure 2).
A univariate Cox proportional hazards analysis identified
predictors of mortality to be age (HR, 1.10, P¼ .09), severe
COPD (HR, 2.36, P ¼ .02), and postoperative stroke (HR,
4.6, P ¼ .01). A multivariate Cox-proportional hazards
model indicated that increasing age (HR, 1.10, P ¼ .007)
and severe COPD (HR, 2.43, P ¼ .02) were the only signif-
icant predictors of survival. By using these factors (Table 2),
a clinical prediction model (chi-square, 15.41; P ¼ .0005)
was developed and demonstrated that low-risk patients (first
quartile prediction score) had 1-, 5-, and 8-year survival of
94%, 84%, and 67%, respectively, whereas high-risk
patients (third quartile prediction score) had 1-, 5-, and
8-year survival of 89%, 74%, and 49%, respectively
(Figure 3).FIGURE 2. Long-term MiniAVR survival compared with an age- and
gender-matched population.
The Journal of Thoracic and CaDISCUSSION
We present the findings of a large-volume, single-institu-
tion study examining the outcomes after MiniAVR in high-
risk patients who may be considered candidates for TAVI.
On the basis of these results, MiniAVR in the current era
can be safely performed in high-risk octogenarians with
a low incidence of morbidity and mortality. These results
are discrepant with current statistical mortality scoring sys-
tems that suggest many of these patients would be at high or
prohibitive surgical risk. In addition, patients in this cohort
sustained a low hazard of morbidity and mortality through
the immediate postoperative phase in addition to the
achievement of an exceptional long-term survival equiva-
lent to that of an age- and gender-matched US population.
On the basis of a multivariate analysis, the only variables
identified that were found to affect long-term survival
were age and COPD. Yet, even patients in the highest risk
quartile achieved excellent postoperative and long-term
outcomes.
The predicted risk of mortality (both the modified Euro-
SCORE and STS score) in this cohort was 11% compared
with the observed mortality risk of 3%. This is the largest
discrepancy between predicted and observed risk in the lit-
erature,14,15,30 and reinforces the concern that current
scoring systems alone should not be used to dictate which
patients are operative candidates. Yet, despite the poor
reliability of these prediction models, current TAVI
clinical trials have relied on them to identify patients who
are at excessive surgical risk. As technology has improved
and the cumulative experience of institutions specializing
in TAVI has increased, the outcomes after TAVI are
promising, but not without significant risk. Operative
mortality ranges between 8.6% and 12%,5,6,8,31,32 and 1-
year mortality ranges between 24% and 26%,5,6,8,31,32
with other major complications occurring in as many as
15% of patients.33 The outcomes of this study (operative
and 1-year cumulative mortality of 3% and 9%, respec-
tively) should not be directly compared with those of the
TAVI trials because no randomization occurred and our co-
hort may have been the result of selection bias effectively
removing high-risk patients from the study base. Our results
do suggest that current models for determining inoperabil-
ity are unreliable, should be used with caution, and should
not unilaterally determine clinical practices, especially in
light of the potential to attain the excellent long-termrdiovascular Surgery c Volume 141, Number 2 331
FIGURE 3. Long-term survival clinical prediction model.
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risk, these models fail to account for a plethora of variables
that are critically important in the determination of proceed-
ing with AVR versus TAVI. Some of these variables would
include frailty, end-stage liver disease, current quality life,
and realistic improvement after surgery.30
We chose to use octogenarians as the main inclusion
criterion simply because elderly patients have the highest
risk profile. One study have found that as many as 40%
of patients aged more than 70 years were denied cardiac sur-
gery34 because of their age. The European Heart Survey,
which was conducted in 25 countries and 92 institutions,
found that approximately 30% of patients were denied aor-
tic valve surgery with age being the one of the most signif-
icant determinants; patients aged more than 80 years were
approximately twice as likely to be denied surgery than
all others simply on the basis of their age.9 The reluctance
to operate on elderly patients is likely to increase referrals
to TAVI despite increasing evidence that AVR in octogenar-
ians and nonagenarians is both safe and confers excellent
outcomes. Comparable to the results of this analysis, a re-
cent study found that patients aged more than 80 years
who underwent AVR had 1-, 2-, and 5-year survival of
87%, 78%, and 68% compared with 52%, 40%, and
22%, respectively, in those who were denied surgery.7
Moreover, survivors achieve a quality of life that is no
different than that of the general population.35
Although there has been evidence that octogenarians un-
dergoing AVR have survival that is similar to the general
population,36 this is the first contribution to the scientific lit-
erature to demonstrate that survival after AVR in octogenar-
ians is not statistically different than that of an age- and
gender-matched US population. This result further empha-
sizes that AVR should be strongly encouraged when there is
confidence that the patient will survive past the immediate
postoperative phase of care. The only predictor of operative
mortality in this cohort was postoperative stroke; a finding
that has been reported in other series examining outcomes
after AVR in octogenarians.16 Six-month mortality was pre-
dicted by female gender and the presence of severe COPD,
whereas long-term survival was predicted by both age and
severe COPD in a multivariate analysis. Yet, even in
patients in the upper tertile of long-term mortality risk,332 The Journal of Thoracic and Cardiovascular Surgsurvival was excellent. As such, we failed to identify a sub-
group of patients in this cohort in whom TAVI may have
been a more appropriate intervention. This reaffirms that
AVR can and should be offered in carefully selected high-
risk patients.
Sincewe first adopted minimally invasive cardiac surgery
in 1996, it has become our approach of choice when
anatomically feasible. As such, we chose to include only
patients who underwent isolated aortic valve surgery via
a minimally invasive approach to minimize confounding
by approach and confounding secondary to concomitant
procedures. The partial mini-upper sternotomy, which re-
duces surgical trauma, has been shown to be associated
with a lower incidence of postoperative stroke, myocardial
infarction, and length of stay, with a greater proportion of
patients being discharged without the need for rehabilita-
tion services.24 Although this cohort study lacks a compari-
son group, it is plausible that the outcomes described may
have been attained in part because of the added benefits
of minimally invasive surgery in a group of patients who
are more susceptible to postoperative morbidity and mortal-
ity. Thus, although minimally invasive surgery has been
well accepted as advantageous, this study confirms its fea-
sibility, beneficial impact on postoperative outcomes, and
long-term survival in high-risk patients requiring AVR.
Limitations
We present the single-institution findings after MiniAVR
in high-risk octogenarians. The intent of this analysis was 2-
fold. First, we aimed to demonstrate that in the current era,
risk-prediction models overestimate the risk of surgery and
thus should not be used to determine which patients are at
prohibitive surgical risk. Second, we aimed to prove that
excellent outcomes after MiniAVR can be achieved in prop-
erly selected patients. Inherent in this analysis is that out-
comes after MiniAVR are superior to those of TAVI;
however, caution should be used when making this conclu-
sion. We do believe, however, that our results provide
evidence that current risk-prediction models are not repre-
sentative of the outcomes after cardiac surgery and thus
should not be unilaterally considered when determining
optimal intervention of severe AS in octogenarians. In addi-
tion, it is important to note that although we describeery c February 2011
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study was not designed or claim to assert that MiniAVR is
superior to traditional AVR via median sternotomy.
CONCLUSIONS
MiniAVR can be performed safely in octogenarians and
can achieve exceptional results when patients are properly
selected. Octogenarians who underwent MiniAVR at Brig-
ham and Women’s Hospital had a low incidence of morbid-
ity and mortality and achieved long-term survival that was
equivalent to that of an age- and gender-matched popula-
tion. Furthermore, these patients had a preoperative risk
of mortality (based on the STS-PROM and modified Euro-
SCORE) that was approximately 5 times greater than the
observed mortality. These results provide a suitable bench-
mark for TAVI clinical trials and indicate that current
risk-prediction models overestimate mortality after cardiac
surgery.
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Dr Craig R. Smith (New York, NY). My disclosure is I am the
surgical principal investigator for the PARTNER trial.
The authors are to be congratulated for demonstrating remark-
ably low mortality in octogenarians who are undergoing conven-
tional surgical AVR. The most important implication of these
findings is that transcatheter techniques should not be extended to
lower-risk patients using age alone as a marker for elevated risk,
which is a critical consideration in trial design and in labeling as
these devices come out. So I think that is an important contribution.
First, I have a comment and a question. My comment first.
I must respectfully object to the implication that MiniAVR as op-
posed to any other kind deserves partial credit for these excellent
mortality results. It would be equally relevant to title this article
‘‘AVR in octogenarians done by varsity surgeons from Boston.’’
Numerous retrospectively matched studies to the contrary notwith-
standing, there is no randomized controlled evidence that a Mini-
AVR reduces mortality, there just isn’t. Variables such as intensive
care unit stay, length of time to discharge, and so forth have been
shown, and although probably innocently, they are easily manipu-
lated by enthusiasts.
Now, how could this be so? I will remind you of the famous in-
ternal thoracic artery study, internal thoracic artery ligation, in
which when restratified according to whether the surgeon was an
enthusiast or a skeptic, the enthusiast’s patients had 40% greater
relief of angina. So the surgeon is a powerful placebo. So when
you are not talking about mortality, very powerful effects. In
a more recent study from the University of Cologne, when subjects
were told they were given a ‘‘lucky’’ ball to putt with that had been
very successful in other people’s hands, they sank 35%more putts.
So I think we should be aware of this and remember that patients
and referring physicians are listening, and embellishing these out-
standing results with a link to a favorite technical trademark only
moves that audience from ignorance to superstition.
Now tomyquestion. I think you are right to be proud of achieving
3% operative mortality in a cohort reported to have an STS score of
14%. This does concern me a little bit for several reasons. I would
love to think that this is a benchmark for the TAVI procedure, as
you suggest, but I do have some concerns. According to the
methods, you included everyone aged more than 80 years having
this procedure. As you probably know, in both the New York State
database and the STS database, an STS score of 14 represents well
less than 5% of the population. Age more than 80 years adds less
than 3% to the STS score. So I have towonder, where did those extra
11 points come from? I don’t think that 10%with renal failurewould
do it, although I could be wrong. Many 90-year-olds have STS
scores less than 10. There is a series from Northwestern this year,
190 patients, who seem to be just as unselected as this cohort, in
which the average STS score in those agedmore than 80 years, there
were 41 of them, was 6. Their operative mortality was 2.4%, similar
to what you reported here. In the operable cohort of the PARTNER
trial, with an average age of 83 years, the STS score is 11.8, similar
to the 12% in the Leipzig series you heard this morning. And any
center that has been involved in this sort of thing knows that that334 The Journal of Thoracic and Cardiovascular Surgquickly eliminates the majority of conventional AVR candidates.
So I will say again, age more than 80 years adds less than 3% to
the risk score. Now, in aggregate, these observations make an aver-
age STS score of 14 extremely surprising for the cohort presented,
selected only by age. So how do you explain an average STS score
that seems impossibly high in this unselected group?
Dr ElBardissi. That is a great question. Thank you, Dr Smith. It
would be difficult for me to go through the details and identify
every factor and how that contributed to the STS score of 14%.
I will say that 20% of our patients had reoperations, and, as you
mentioned, 10% of patients had renal failure. This was a particu-
larly sick cohort of patients, and although I would love to have
how every factor contributed to that mean score, I just don’t
have that information right now.
Dr Smith. I wouldn’t expect you to.
Dr Robert J. Cusimano (Toronto, Ontario, Canada). Along
the lines of the other one, whenever we look at someone for a trans-
catheter valve, a lot of the times there is a calcified aorta and some-
times there is this word frailty; the reason we accept them is
because of frailty. How have you been able to tease the frailty
part of the whole thing, and the second question is, how many of
your patients had calcified aortas and what do you do with those
patients?
Dr ElBardissi. I think it is important to note that our institution
is also participating in the PARTNER trial. So this is not meant to
be a presentation saying everyone should have an open AVR.
I think what you are identifying is what a number of studies
have identified, which is there are a number of factors that aren’t
included in the STS score, such as patient frailty, porcelain aorta,
severe liver failure, which generally are thought to contribute sig-
nificantly to patient mortality, but, again, are not included in the
STS score.
Patients who have a completely calcified aorta not amenable at
all to cancellation are those whom we would generally refer and
include in the PARTNER trial. These are highly select patients.
These are obviously patients who underwent the scrutiny of sur-
geons and cardiologists and were deemed to be operative candi-
dates for surgical AVR. So you can probably say that these are
relatively healthy high-risk patients.
Dr Thoralf Sundt (Rochester, Minn). I appreciate that the in-
tent of this presentation is really more to compare surgical AVR
with percutaneous AVR, but, predictably, my question, much
like Craig’s, relates to the value of the ‘‘mini’’ component of
this. If I understand correctly, you have sacrificed antegrade perfu-
sion for femoral artery perfusion to gain 3 inches of sternum, and
you have a fair number of strokes. Can you tell me anything about
those strokes and make me feel better about pumping these people
from the groin? These folks are 80 years old, and a lot of them have
a lot of calcium in their descending thoracic aortas.
DrElBardissi. I can tell you that 4% of our patients had strokes,
and I reviewed all these strokes. The majority of those were small
strokes the patient recovered from. There were a couple that were
pretty significant strokes. I still don’t think a 4% stroke rate in this
cohort of patients, though, is really that significant and should de-
ter someone from providing patients with a long-lasting AVR
when they may very well make it through the postoperative phase
with no complications. In fact, they would be likely to get through
the postoperative phase with no complications.ery c February 2011
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Moon CommentaryDr Sundt. And I agree with you. I didn’t mean to take a shot at
you for the 4% rate in the primary cases or the 8% in the redos. The
real question, though, is, would the stroke rate have been less if
they had been perfused from the ascending aorta rather than
from the groin? But I appreciate that it is difficult to answer that
question.
Dr Bolman. Well, they are perfused antegrade. The patients
receive percutaneous venous but central aortic cannulation.
Dr Sundt. It was only percutaneous femoral?
Dr ElBardissi. They are cannulated centrally and perfused cen-
trally except in reoperations, in which case they are perfused pe-
ripherally through the femoral artery or they are perfused
through the axillary artery, but in all primary operations they are
perfused through the aorta.
Dr Sundt. I am sorry I misunderstood. Thank you very much.
Dr Hillel Laks (Los Angeles, Calif). One of the factors that was
not discussed in the article on robotic mitral valve surgery that we
just heard or in this article on MiniAVRwas the effects of these ap-
proaches on the brain, on neurocognitive function. One of the great
concerns that many surgeons have is the issue of de-airing of the
heart at the end of these procedures, which has been shown by
transcranial Doppler to shower the brain with microemboli, andCOMMEN
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The Journal of Thoracic and Cathe literature is replete with studies retrospectively that have shown
30% of patients having some neurocognitive dysfunctions. Do you
know of any studies that have been done to compare these ap-
proaches, and particularly this one, in terms of neurocognitive func-
tion recovery, which is particularly pertinent to the old age group?
Dr ElBardissi.As far as neurocognitive function, if we are talk-
ing about these transient, diffuse neurocognitive dysfunction epi-
sodes, I don’t know of any studies. If we are talking about acute
events such as strokes or transient ischemic attacks, I can tell
you that our institution did a retrospective study that was published
in the Annals of Surgery and found no significant difference be-
tween the minimally invasive approach and the open approach
as far as those acute events are concerned.
Dr Laks. I would like to emphasize that the incidence of clin-
ically apparent strokes underrepresents diffuse brain injury that
can result in neurocognitive dysfunction and that can be present
as long as 6 months after surgery, and it is thought that many of
those may be permanent. I think before we declare that these
approaches are superior or equal, a randomized or equivalent
type of study needs to be done looking at neurocognitive function
both for robotic mitral valve surgery and for other minimally
invasive approaches.TARYPredictive value of surgical scoring systems in determining operative
risk for octogenarians undergoing aortic valve replacementMarc R. Moon, MDIn a retrospective, single-center study, ElBardissi and asso-
ciates1 report the results of isolated aortic valve replacement
(AVR) in 249 octogenarians from 1996 to 2009, during which
time they performed a minimally invasive approach in almost
all patients. This study does not compare the minimally
invasive approach with the traditional AVR via median ster-
notomy, so any conclusions as to the impact of a particular
surgical approach would not be reasonable. Therefore, I will
make no reference to the specific surgical technique, but referonly to AVR in general. The authors’ specific aims included
the following: (1) demonstrate that AVR can be performed
safely in high-risk patients; (2) document long-term survival
as a benchmark for future studies; and (3) assess the reliability
of two current risk-prediction models, The Society of
Thoracic Surgeons Predicted Risk of Mortality (STS-
PROM)andmodifiedEuropeanSystemforCardiacOperative
Risk Evaluation (EuroSCORE) algorithms,2,3 hypothesizing
that these current risk-prediction models ‘‘overestimate risk
in appropriately chosen and optimized patients.’’ Although
the authors were successful in addressing specific aims 1
and 2, they may have fallen short in their assessment of the
STS-PROM and EuroSCORE risk score algorithms.SPECIFIC AIM 1
The authors report operative mortality of 3% 2% (95%
confidence limit) for octogenarians undergoing AVR during
this modern era. Mean ventilator duration was 16  27rdiovascular Surgery c Volume 141, Number 2 335
